JP2013520984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520984A5 JP2013520984A5 JP2012555532A JP2012555532A JP2013520984A5 JP 2013520984 A5 JP2013520984 A5 JP 2013520984A5 JP 2012555532 A JP2012555532 A JP 2012555532A JP 2012555532 A JP2012555532 A JP 2012555532A JP 2013520984 A5 JP2013520984 A5 JP 2013520984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cdr3 sequences
- light chain
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 81
- 102000004965 antibodies Human genes 0.000 claims 81
- 101700027814 CDR3 Proteins 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 24
- 210000004027 cells Anatomy 0.000 claims 11
- 102100016662 ERBB2 Human genes 0.000 claims 10
- 101700025368 ERBB2 Proteins 0.000 claims 10
- 101710037934 QRSL1 Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 210000004881 tumor cells Anatomy 0.000 claims 2
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 1
- 102000001301 EGF receptors Human genes 0.000 claims 1
- 108060006698 EGF receptors Proteins 0.000 claims 1
- 108010010691 Trastuzumab Proteins 0.000 claims 1
- 230000003024 amidolytic Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31055210P | 2010-03-04 | 2010-03-04 | |
| DKPA201070085 | 2010-03-04 | ||
| DKPA201070085 | 2010-03-04 | ||
| US61/310,552 | 2010-03-04 | ||
| US35413310P | 2010-06-11 | 2010-06-11 | |
| US61/354,133 | 2010-06-11 | ||
| US201061428014P | 2010-12-29 | 2010-12-29 | |
| US61/428,014 | 2010-12-29 | ||
| PCT/IB2011/050903 WO2011107957A1 (en) | 2010-03-04 | 2011-03-03 | Anti-her2 antibodies and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016123623A Division JP2016182135A (ja) | 2010-03-04 | 2016-06-22 | 抗ｈｅｒ２抗体および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520984A JP2013520984A (ja) | 2013-06-10 |
| JP2013520984A5 true JP2013520984A5 (hr) | 2014-04-24 |
| JP6039428B2 JP6039428B2 (ja) | 2016-12-07 |
Family
ID=44541704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555532A Expired - Fee Related JP6039428B2 (ja) | 2010-03-04 | 2011-03-03 | 抗ｈｅｒ２抗体および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2542589A4 (hr) |
| JP (1) | JP6039428B2 (hr) |
| CN (1) | CN102884084B (hr) |
| TW (1) | TW201141519A (hr) |
| WO (1) | WO2011107957A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883149B2 (en) | 2008-09-15 | 2014-11-11 | Yeda Research And Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| CA2816520C (en) | 2010-11-01 | 2017-11-21 | Symphogen A/S | Anti-her3 antibodies and compositions |
| EP2710038B1 (en) | 2011-05-16 | 2018-01-17 | Yeda Research and Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| CN104428318B (zh) | 2012-05-02 | 2018-09-25 | 西福根有限公司 | 人源化泛her抗体组合物 |
| EP3838923B1 (en) | 2012-08-24 | 2024-05-01 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| RU2656161C1 (ru) * | 2013-11-19 | 2018-05-31 | Ремеджен, Лтд. | Анти-неr2 антитело и его конъюгат |
| CN104974261B (zh) * | 2014-04-01 | 2019-06-14 | 三生国健药业（上海）股份有限公司 | 重组抗her2/ps双特异性抗体、其制备方法和应用 |
| BR112017011170A2 (pt) * | 2014-12-18 | 2018-02-27 | Hoffmann La Roche | método para determinar a citotoxicidade dependente do complemento de uma composição |
| CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| CN109154600A (zh) * | 2016-06-16 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于确定cdc诱导抗体的测定法和方法 |
| SG11201811559WA (en) | 2016-06-27 | 2019-01-30 | Univ California | Cancer treatment combinations |
| CN107137424A (zh) * | 2017-05-15 | 2017-09-08 | 广州领晟医疗科技有限公司 | 一种利用正常小鼠建立her2阳性肿瘤的动物模型的方法 |
| WO2019173911A1 (en) * | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
| CN109134656A (zh) * | 2018-09-12 | 2019-01-04 | 四川妙和生物科技有限公司 | 一种抗her2多克隆抗体 |
| WO2020191434A1 (en) * | 2019-03-22 | 2020-10-01 | Olivia Newton-John Cancer Research Institute | Anti-her2 binding molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244826B1 (en) * | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6794128B2 (en) * | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| JP2006516117A (ja) * | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療 |
| GB0503546D0 (en) * | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| JP5719298B2 (ja) * | 2008-08-29 | 2015-05-13 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | 組換え抗上皮増殖因子受容体抗体組成物 |
-
2011
- 2011-03-03 EP EP11750275.7A patent/EP2542589A4/en not_active Withdrawn
- 2011-03-03 CN CN201180022307.6A patent/CN102884084B/zh not_active Expired - Fee Related
- 2011-03-03 WO PCT/IB2011/050903 patent/WO2011107957A1/en active Application Filing
- 2011-03-03 JP JP2012555532A patent/JP6039428B2/ja not_active Expired - Fee Related
- 2011-03-03 TW TW100107086A patent/TW201141519A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520984A5 (hr) | ||
| RU2504553C2 (ru) | Антитела к her | |
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| RU2019110835A (ru) | Антитела к pd-1(cd279) | |
| JP2020532965A5 (hr) | ||
| JP2018503380A5 (hr) | ||
| JP2010246565A5 (hr) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| JP2018521638A5 (hr) | ||
| JP2016526904A5 (hr) | ||
| JP2010526028A5 (hr) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| JP2014503189A5 (hr) | ||
| JP2020503001A5 (hr) | ||
| JP2014526898A5 (hr) | ||
| KR20160056880A (ko) | 항garp 단백질 항체와 그 용도 | |
| JP2014534242A5 (hr) | ||
| JP2013538057A5 (hr) | ||
| JP2013545455A5 (hr) | ||
| JP2009545325A5 (hr) | ||
| WO2015032906A4 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| JP2013539369A5 (hr) | ||
| JP2017534259A5 (hr) | ||
| JP2010509931A5 (hr) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 |